Profile data is unavailable for this security.
About the company
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
- Revenue in USD (TTM)62.58bn
- Net income in USD7.75bn
- Incorporated1942
- Employees81.00k
- LocationPfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.pfizer.com/
Mergers & acquisitions
| Acquired company | PFE:NYQ since announced | Transaction value |
|---|---|---|
| Metsera Inc | 14.90% | 9.74bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 14.34bn | 4.55bn | 79.81bn | 15.41k | 17.99 | 2.55 | 15.67 | 5.56 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Vertex Pharmaceuticals Inc | 11.72bn | 3.68bn | 117.59bn | 6.10k | 32.57 | 6.80 | 30.34 | 10.03 | 14.23 | 14.23 | 45.38 | 68.20 | 0.4978 | 1.19 | 6.34 | 1,921,853.00 | 15.60 | 14.06 | 19.02 | 16.67 | 86.28 | 87.35 | 31.35 | 26.28 | 2.00 | -- | 0.00 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Bristol-Myers Squibb Co | 48.19bn | 7.05bn | 123.90bn | 34.10k | 17.60 | -- | 11.35 | 2.57 | 3.46 | 3.46 | 23.63 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 72.62 | 76.32 | 14.64 | 8.34 | -- | 16.84 | -- | -- | -0.2195 | 2.54 | 178.83 | -- | -- | 0.658 |
| Pfizer Inc | 62.58bn | 7.75bn | 156.98bn | 81.00k | 20.37 | -- | 11.28 | 2.51 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Gilead Sciences Inc | 29.44bn | 8.51bn | 182.67bn | 17.60k | 21.71 | 8.08 | 21.74 | 6.20 | 6.78 | 6.78 | 23.46 | 18.23 | 0.499 | 2.05 | 6.31 | -- | 14.42 | 8.03 | 18.05 | 9.82 | 78.84 | 78.01 | 28.91 | 18.13 | 1.31 | 36.91 | -- | 73.41 | 2.40 | 3.58 | 1,672.92 | 133.35 | -- | 3.04 |
| Amgen Inc | 36.75bn | 7.71bn | 196.36bn | 28.00k | 25.62 | 22.70 | 18.77 | 5.34 | 14.23 | 14.23 | 67.84 | 16.06 | 0.4029 | 1.48 | 4.49 | -- | 8.45 | 7.90 | 11.52 | 10.18 | 73.30 | 74.68 | 20.98 | 20.55 | 0.8958 | 18.59 | 0.8631 | 72.99 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 483.66m | 8.51% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 299.09m | 5.26% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 294.15m | 5.17% |
| Geode Capital Management LLCas of 30 Sep 2025 | 129.01m | 2.27% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 93.65m | 1.65% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2025 | 66.95m | 1.18% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 57.32m | 1.01% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 55.76m | 0.98% |
| BlackRock Advisors (UK) Ltd.as of 30 Sep 2025 | 54.97m | 0.97% |
| State Farm Investment Management Corp.as of 30 Sep 2025 | 54.51m | 0.96% |
